Tolvaptan OK Would Require Unusual Tolerance Of Drug-Induced Liver Injury
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA advisory committee briefing docs indicate odds stacked against Otsuka’s tolvaptan kidney disease indication without better efficacy data to counteract drug-induced liver injury risk.
You may also be interested in...
FDA Panel To Weigh Unmet Need Vs. Liver Injury With Samsca Kidney Indication
Risk of drug-induced injury is likely to complicate an Aug. 5 advisory committee review of Otsuka’s kidney drug tolvaptan.
Woodcock Takes On Rare Disease Challenges In Retirement, Keeps FDA, Industry At Arm’s Length
Recently retired US FDA Principal Deputy Commissioner Janet Woodcock will be advising the Haystack Project, with the goal of helping rare disease organizations encourage creativity in drug development programs without jeopardizing regulatory success, Woodcock told the Pink Sheet in an interview.
Patent Office Issues Proposed Rule For Rarely Successful Director Review Requests
The rulemaking is supposed to formalize the Patent Trial and Appeal Board process, which has been in an interim status since a Supreme Court decision, giving manufacturers more ability to request oversight of the decisions.